- Email: [email protected]
Social Responsibilities of Oncology Medical Association in Taiwan
Annals of Oncology 30 (Supplement 6): vi5, 2019 doi:10.1093/annonc/mdz301
ASIA OCEANIA/JSMO JOINT SYMPOSIUM : JOINT SYMPOSIUM OF ASIAN MEDICAL ONCOLOGY SOCIETIES TO FURTHER DEVELOP RELATIONSHIP FOR ASIAN PATIENTS 2
An overview of innovative cancer drug clinical development in China
Junli Xue Oncology Department, Shanghai East Hospital, Tongji University, China China starts to play more and more important role in the global arena of cancer drug development. From investigator’s perspective, this talk provides an overview of China cancer drug development, and strategy for future success. There are gaps between China and other countries in investment and length of drug development. With regulation reforms, cases show the drug development speed has been significantly improved. Large oncology patient population and unmet medical need make China an attractive market for cancer drug development. However, there is a big potential to be unleashed in early phase studies including phase I cancer trials in China. This talk also shares experience of how to build such an early clinical trial platform, with a professional clinical trial team, efficient management model and advanced technologies. Based on current situation, we need to discuss how to accelerate anticancer new drug research and develop more efficient and economic drugs for both China and Asian cancer patients.
AOJS
3
Social Responsibilities of Oncology Medical Association in Taiwan
Oncology Nursing Society, Taiwan Psycho-Oncology Society, HOPE Foundation for Cancer Care initiated an annual Cancer Survivorship Symposium since the year of 2015. The main purpose is to provide patient-centered seamless cancer care between hospital and community through the linkage of all stakeholders including professional medical association, hospital service, government and non-governmental organization. Many issues, such as how to empower patient to deal with cancer, how to link all the resources for patient care effectively, how to alert the right of fertility preservation, how to co-operate with NGO to support the patient centricity clinical trial, have been fully discussed. The detail will be presented in the conference meeting.
AOJS
4
Challenges of Cancer Care in Singapore
Su Pin Choo Singapore Society of Oncology, Singapore Asia accounts for 60% of the world population, and half the global burden of cancer. The incidence of cancer cases is estimated to increase to 70% by 2030, in part due to a growing aging population, lifestyle and socioeconomic changes. The costs of cancer care can be staggering and Singapore has the challenge of meeting the cancer needs of an aging population while trying to reign in escalating healthcare costs. The challenges faced in delivering optimal cancer care in Singapore is not much different from those experienced by developed countries.
Li-Tzong Chen1, Cheng-Su Wang2,3,4 President of Taiwan Oncology Society(TOS)/National Institute of Cancer Research National Health Research Institutes, Taiwan, 2Taiwan Oncology Society, 3Department of Internal Medicine, Chang Gung Memorial Hospital, Keelong, 4HOPE Foundation for Cancer Care, Taipei, Taiwan 1
In the era of 2010, cure for cancer is not the end. Both during and after anticancer management, cancer patients need a variety of supports to facilitate their recovery. In order to meet these cancer care needs, Taiwan Oncology Society in conjunction with Taiwan
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz301.001/5582770 by University of Cambridge user on 06 November 2019
AOJS
ASIA OCEANIA/JSMO JOINT SYMPOSIUM : JOINT SYMPOSIUM OF ASIAN MEDICAL ONCOLOGY SOCIETIES TO FURTHER DEVELOP RELATIONSHIP FOR ASIAN PATIENTS 2
An overview of innovative cancer drug clinical development in China
Junli Xue Oncology Department, Shanghai East Hospital, Tongji University, China China starts to play more and more important role in the global arena of cancer drug development. From investigator’s perspective, this talk provides an overview of China cancer drug development, and strategy for future success. There are gaps between China and other countries in investment and length of drug development. With regulation reforms, cases show the drug development speed has been significantly improved. Large oncology patient population and unmet medical need make China an attractive market for cancer drug development. However, there is a big potential to be unleashed in early phase studies including phase I cancer trials in China. This talk also shares experience of how to build such an early clinical trial platform, with a professional clinical trial team, efficient management model and advanced technologies. Based on current situation, we need to discuss how to accelerate anticancer new drug research and develop more efficient and economic drugs for both China and Asian cancer patients.
AOJS
3
Social Responsibilities of Oncology Medical Association in Taiwan
Oncology Nursing Society, Taiwan Psycho-Oncology Society, HOPE Foundation for Cancer Care initiated an annual Cancer Survivorship Symposium since the year of 2015. The main purpose is to provide patient-centered seamless cancer care between hospital and community through the linkage of all stakeholders including professional medical association, hospital service, government and non-governmental organization. Many issues, such as how to empower patient to deal with cancer, how to link all the resources for patient care effectively, how to alert the right of fertility preservation, how to co-operate with NGO to support the patient centricity clinical trial, have been fully discussed. The detail will be presented in the conference meeting.
AOJS
4
Challenges of Cancer Care in Singapore
Su Pin Choo Singapore Society of Oncology, Singapore Asia accounts for 60% of the world population, and half the global burden of cancer. The incidence of cancer cases is estimated to increase to 70% by 2030, in part due to a growing aging population, lifestyle and socioeconomic changes. The costs of cancer care can be staggering and Singapore has the challenge of meeting the cancer needs of an aging population while trying to reign in escalating healthcare costs. The challenges faced in delivering optimal cancer care in Singapore is not much different from those experienced by developed countries.
Li-Tzong Chen1, Cheng-Su Wang2,3,4 President of Taiwan Oncology Society(TOS)/National Institute of Cancer Research National Health Research Institutes, Taiwan, 2Taiwan Oncology Society, 3Department of Internal Medicine, Chang Gung Memorial Hospital, Keelong, 4HOPE Foundation for Cancer Care, Taipei, Taiwan 1
In the era of 2010, cure for cancer is not the end. Both during and after anticancer management, cancer patients need a variety of supports to facilitate their recovery. In order to meet these cancer care needs, Taiwan Oncology Society in conjunction with Taiwan
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz301.001/5582770 by University of Cambridge user on 06 November 2019
AOJS